
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8426589/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Maternal SARS-CoV-2 infection during pregnancy: possible impact on the infant. European Journal of Pediatrics, 2022, 181, 413-418.	1.3	14
2	Pregnant and Postpartum Women Requiring Intensive Care Treatment for COVID-19—First Data from the CRONOS-Registry. Journal of Clinical Medicine, 2022, 11, 701.	1.0	24
3	OUP accepted manuscript. Human Molecular Genetics, 2022, , .	1.4	1
4	Prevalence of SARS-CoV-2 in Pregnant Women Assessed by RT-PCR in Franconia, Germany: First Results of the SCENARIO Study (SARS-CoV-2 prEvalence in pregNAncy and at biRth In FrancOnia). Geburtshilfe Und Frauenheilkunde, 2022, 82, 226-234.	0.8	6
5	Decision Conflicts in Clinical Care during COVID-19: A Patient Perspective. Healthcare (Switzerland), 2022, 10, 1019.	1.0	5
6	Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics $\hat{a} \in \hat{a}$ A retrospective analysis of a real world registry. European Journal of Cancer, 2022, 172, 13-21.	1.3	1
7	Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. Clinical Cancer Research, 2022, 28, 3342-3355.	3.2	3
8	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	1.1	12
9	Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Breast Care, 2021, 16, 254-262.	0.8	0
10	Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer. International Journal of Cancer, 2021, 148, 307-319.	2.3	35
11	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines. Breast Care, 2021, 16, 291-298.	0.8	2
12	Odontoblast TRPC5 channels signal cold pain in teeth. Science Advances, 2021, 7, .	4.7	42
13	Association of genomic variants at <scp><i>PAX8</i></scp> and <scp><i>PBX2</i></scp> with cervical cancer risk. International Journal of Cancer, 2021, 149, 893-900.	2.3	7
14	Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy. , 2021, 9, e002605.		7
15	Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus. Human Genetics, 2021, 140, 1353-1365.	1.8	18
16	Comprehensive characterization of endometriosis patients and disease patterns in a large clinical cohort. Archives of Gynecology and Obstetrics, 2021, , 1.	0.8	2
17	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. European Journal of Cancer, 2021, 155, 1-12.	1.3	39
18	Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. Gynecologic Oncology, 2021, 162, 652-660.	0.6	17

#	Article	IF	CITATIONS
19	Mammographic density and prognosis in primary breast cancer patients. Breast, 2021, 59, 51-57.	0.9	13
20	Long-term outcome of patients with intermediate- and high-risk endometrial cancer after pelvic and paraaortic lymph node dissection: a comparison of laparoscopic vs. open procedure. Journal of Cancer Research and Clinical Oncology, 2020, 146, 961-969.	1.2	8
21	Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma. Archives of Gynecology and Obstetrics, 2020, 301, 289-294.	0.8	5
22	HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. Scientific Reports, 2020, 10, 15750.	1.6	15
23	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center in Relation to Complementary and Alternative Medicine. Complementary Medicine Research, 2020, 27, 431-439.	0.5	3
24	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	2.9	35
25	Association of genomic variants at the human leukocyte antigen locus with cervical cancer risk, HPV status and gene expression levels. International Journal of Cancer, 2020, 147, 2458-2468.	2.3	12
26	Analysis of motives and patient satisfaction in oncological second opinions provided by a certified university breast and gynecological cancer center. Archives of Gynecology and Obstetrics, 2020, 301, 1299-1306.	0.8	6
27	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2020, 21, 699-709.	5.1	104
28	A phase II single-arm, multicenter, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple-negative breast cancer: Neoimmunoboost Journal of Clinical Oncology, 2020, 38, e12647-e12647.	0.8	0
29	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	2.3	28
30	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	1.6	5
31	Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study. BMC Cancer, 2019, 19, 611.	1.1	5
32	Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients. International Journal of Cancer, 2019, 145, 2114-2121.	2.3	6
33	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2019, 175, 617-625.	1.1	35
34	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	2.9	52
35	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
36	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. Breast Cancer Research and Treatment, 2019, 174, 453-461.	1.1	15

#	Article	IF	CITATIONS
37	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. Breast Cancer Research and Treatment, 2019, 173, 319-328.	1.1	40
38	Functional Analysis and Fine Mapping of the 9p22.2 Ovarian Cancer Susceptibility Locus. Cancer Research, 2019, 79, 467-481.	0.4	22
39	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	0.9	81
40	TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes. Breast Care, 2018, 13, 8-14.	0.8	32
41	Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. European Journal of Cancer, 2018, 96, 82-90.	1.3	36
42	Genetic overlap between endometriosis and endometrial cancer: evidence from crossâ€disease genetic correlation and GWAS metaâ€analyses. Cancer Medicine, 2018, 7, 1978-1987.	1.3	62
43	Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety. Naunyn-Schmiedeberg's Archives of Pharmacology, 2018, 391, 219-229.	1.4	3
44	BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. Breast Cancer Research and Treatment, 2018, 171, 85-94.	1.1	56
45	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	0.9	15
46	Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients. Annals of Oncology, 2018, 29, 186-192.	0.6	35
47	A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients. Annals of Oncology, 2018, 29, viii72.	0.6	0
48	Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. BMC Cancer, 2018, 18, 1051.	1.1	59
49	Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria,) Tj ETQq1 1 0.7	784314 rg	BT ³ Óverlock
50	Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. Frontiers in Pharmacology, 2018, 9, 158.	1.6	21
51	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	1.1	9
52	Identification of nine new susceptibility loci for endometrial cancer. Nature Communications, 2018, 9, 3166.	5.8	178
53	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	1.8	3
54	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians. Geburtshilfe Und Frauenheilkunde, 2018, 78, 707-714.	0.8	3

#	Article	IF	CITATIONS
55	Risk, Prediction and Prevention of Hereditary Breast Cancer – Large-Scale Genomic Studies in Times of Big and Smart Data. Geburtshilfe Und Frauenheilkunde, 2018, 78, 481-492.	0.8	38
56	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	9.4	184
57	Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with recurrent epithelial ovarian carcinoma (EOC) after complete response (CR) to 1st-line platinum (Pt)-based ct: Primary analysis of a phase 2, open-label, randomized, multicenter trial Journal of Clinical Oncology, 2018, 36, e17515-e17515.	0.8	4
58	Genetic risk factors for ovarian cancer and their role for endometriosis risk. Gynecologic Oncology, 2017, 145, 142-147.	0.6	24
59	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
60	Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis. Breast Cancer Research and Treatment, 2017, 166, 701-708.	1.1	12
61	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	3.4	260
62	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
63	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
64	Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study. Geburtshilfe Und Frauenheilkunde, 2017, 77, 651-659.	0.8	14
65	Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. Geburtshilfe Und Frauenheilkunde, 2017, 77, 667-678.	0.8	21
66	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	1.1	3
67	Interest in Integrative Medicine Among Postmenopausal Hormone Receptor–Positive Breast Cancer Patients in the EvAluate-TM Study. Integrative Cancer Therapies, 2017, 16, 165-175.	0.8	22
68	Body mass index and breast cancer survival: a Mendelian randomization analysis. International Journal of Epidemiology, 2017, 46, 1814-1822.	0.9	45
69	Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity. Oncotarget, 2017, 8, 78133-78143.	0.8	6
70	Abstract P5-16-18: The effect of participation in neoadjuvant clinical trials on outcomes in patients with early breast cancer. , 2017, , .		0
71	<i>PALB2</i> , <i>CHEK2</i> and <i>ATM</i> rare variants and cancer risk: data from COGS. Journal of Medical Genetics, 2016, 53, 800-811.	1.5	174
72	Neoadjuvant Treatment of Breast Cancer - Advances and Limitations. Breast Care, 2016, 11, 313-314.	0.8	12

#	Article	IF	CITATIONS
73	The PI3K Pathway: Background and Treatment Approaches. Breast Care, 2016, 11, 398-404.	0.8	28
74	Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. Breast Care, 2016, 11, 315-322.	0.8	6
75	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	1.8	19
76	Five endometrial cancer risk loci identified through genome-wide association analysis. Nature Genetics, 2016, 48, 667-674.	9.4	77
77	A Review of Integrative Medicine in Gynaecological Oncology. Geburtshilfe Und Frauenheilkunde, 2016, 76, 150-155.	0.8	19
78	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	0.9	111
79	Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 1503-1510.	1.1	64
80	Chylous ascites after lymphadenectomy for gynecological malignancies. Journal of Surgical Oncology, 2016, 114, 613-618.	0.8	11
81	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. Breast Cancer Research and Treatment, 2016, 158, 59-65.	1.1	27
82	CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocrine-Related Cancer, 2016, 23, 77-91.	1.6	62
83	Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor. Archives of Gynecology and Obstetrics, 2016, 294, 343-351.	0.8	21
84	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	0.5	37
85	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	0.6	18
86	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	0.8	5
87	Germline polymorphisms in an enhancer of <i>PSIP1</i> are associated with progression-free survival in epithelial ovarian cancer. Oncotarget, 2016, 7, 6353-6368.	0.8	29
88	Abstract B32: Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cancer Research, 2016, 76, B32-B32.	0.4	1
89	Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1. Scientific Reports, 2015, 5, 17369.	1.6	35
90	Endometriosis as a risk factor for ovarian or endometrial cancer — results of a hospital-based case–control study. BMC Cancer, 2015, 15, 751.	1.1	25

#	Article	IF	CITATIONS
91	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	0.6	22
92	Common germline polymorphisms associated with breast cancer-specific survival. Breast Cancer Research, 2015, 17, 58.	2.2	26
93	Genetic variants in <scp>VEGF</scp> pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III <scp>G</scp> epar <scp>Q</scp> uinto study. International Journal of Cancer, 2015, 137, 2981-2988.	2.3	31
94	Association of molecular subtypes with breast cancer risk factors. European Journal of Cancer Prevention, 2015, 24, 484-490.	0.6	14
95	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	1.1	44
96	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	1.4	40
97	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	9.4	221
98	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	9.4	513
99	Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 2015, 47, 888-897.	9.4	78
100	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i> -Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	1.1	28
101	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	3.2	33
102	Identification of Novel Genetic Markers of Breast Cancer Survival. Journal of the National Cancer Institute, 2015, 107, .	3.0	56
103	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	0.6	15
104	Candidate locus analysis of the TERT–CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk. Human Genetics, 2015, 134, 231-245.	1.8	34
105	Hormone Therapy and its Effect on the Prognosis in Breast Cancer Patients. Geburtshilfe Und Frauenheilkunde, 2015, 75, 588-596.	0.8	11
106	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	5.8	63
107	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	1.3	24
108	Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases. BMC Cancer, 2015, 15, 587.	1.1	19

#	Article	IF	CITATIONS
109	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	1.4	68
110	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell, 2015, 162, 974-986.	13.5	1,408
111	Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer. Endocrine-Related Cancer, 2015, 22, 851-861.	1.6	25
112	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 2015, 24, 1478-1492.	1.4	50
113	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
114	Abstract 5488: Utilizing a pathway based analysis of genome wide association data to identify biomarkers of toxicity in breast cancer patients. , 2015, , .		0
115	Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. Breast Cancer Research and Treatment, 2014, 148, 143-151.	1.1	45
116	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. British Journal of Cancer, 2014, 111, 2297-2307.	2.9	76
117	Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma. BioMed Research International, 2014, 2014, 1-9.	0.9	38
118	Variation in NF-κB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	1.1	13
119	Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study. Geburtshilfe Und Frauenheilkunde, 2014, 74, 1137-1143.	0.8	11
120	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2014, 23, 6096-6111.	1.4	53
121	ABCA Transporter Gene Expression and Poor Outcome in Epithelial Ovarian Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	107
122	Risk of Ovarian Cancer and the NF-κB Pathway: Genetic Association with <i>IL1A</i> and <i>TNFSF10</i> . Cancer Research, 2014, 74, 852-861.	0.4	48
123	Large-Scale Evaluation of Common Variation in Regulatory T Cell–Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	1.6	21
124	Polymorphisms in the <i>RANK/RANKL</i> Genes and Their Effect on Bone Specific Prognosis in Breast Cancer Patients. BioMed Research International, 2014, 2014, 1-7.	0.9	18
125	Comprehensive visualization of paresthesia in breast cancer survivors. Archives of Gynecology and Obstetrics, 2014, 290, 135-141.	0.8	11
126	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	1.8	23

#	Article	IF	CITATIONS
127	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis, 2014, 35, 1012-1019.	1.3	145
128	Consortium analysis of gene and gene–folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	1.5	16
129	FCF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. British Journal of Cancer, 2014, 110, 1088-1100.	2.9	21
130	Response to "Screening depression during and after pregnancy using the EPDS― Archives of Gynecology and Obstetrics, 2014, 290, 603-603.	0.8	0
131	Socioeconomic status and depression during and after pregnancy in the Franconian Maternal Health Evaluation Studies (FRAMES). Archives of Gynecology and Obstetrics, 2014, 289, 755-763.	0.8	39
132	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	9.4	326
133	Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. Breast Cancer Research and Treatment, 2013, 139, 429-440.	1.1	29
134	Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. Breast Cancer Research and Treatment, 2013, 138, 899-908.	1.1	23
135	Breast Cancer Risk – From Genetics to Molecular Understanding of Pathogenesis. Geburtshilfe Und Frauenheilkunde, 2013, 73, 1228-1235.	0.8	33
136	Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 216-223.	1.1	22
137	Hormone replacement therapy and prognosis in ovarian cancer patients. European Journal of Cancer Prevention, 2013, 22, 52-58.	0.6	28
138	Mutation status of the mediator complex subunit 12 (MED12) in uterine leiomyomas and concurrent/metachronous multifocal peritoneal smooth muscle nodules (leiomyomatosis) Tj ETQq0 0 0 rgBT /Ov	erlousk 10	Tf 5 40 297 Td
139	Amplified Cold Transduction in Native Nociceptors by M-Channel Inhibition. Journal of Neuroscience, 2013, 33, 16627-16641.	1.7	37
140	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 987-992.	1.1	20
141	The UGT1A6_19_GG genotype is a breast cancer risk factor. Frontiers in Genetics, 2013, 4, 104.	1.1	8
142	Percent Mammographic Density and Dense Area as Risk Factors for Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2012, 72, 727-733.	0.8	31
143	Circulating Micro-RNAs as Potential Blood-Based Markers for Early Stage Breast Cancer Detection. PLoS ONE, 2012, 7, e29770.	1.1	219
144	Characterizing mammographic images by using generic texture features. Breast Cancer Research, 2012, 14, R59.	2.2	65

#	Article	IF	CITATIONS
145	Accuracy of radiological tumour size assessment and the risk for re-excision in a cohort of primary breast cancer patients. European Journal of Surgical Oncology, 2012, 38, 44-51.	0.5	26
146	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 980-987.	1.1	32
147	Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). PLoS ONE, 2012, 7, e42380.	1.1	51
148	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	1.4	152
149	Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. BMC Cancer, 2011, 11, 486.	1.1	260
150	Transient receptor potential cation channel, subfamily C, member 5 (TRPC5) is a cold-transducer in the peripheral nervous system. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18114-18119.	3.3	192
151	Mammographic density as a risk factor for breast cancer in a German case–control study. European Journal of Cancer Prevention, 2011, 20, 1-8.	0.6	53
152	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. Nature Genetics, 2011, 43, 451-454.	9.4	141
153	Diabetes and prognosis in a breast cancer cohort. Journal of Cancer Research and Clinical Oncology, 2011, 137, 975-983.	1.2	59
154	Breast Cancer Risk – Genes, Environment and Clinics. Geburtshilfe Und Frauenheilkunde, 2011, 71, 1056-1066.	0.8	55
155	Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. British Journal of Cancer, 2011, 105, 1934-1939.	2.9	4
156	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e20703.	1.1	21
157	Assessment of mammographic density before and after first full-term pregnancy. European Journal of Cancer Prevention, 2010, 19, 405-412.	0.6	21
158	Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. Breast Cancer Research and Treatment, 2010, 121, 101-110.	1.1	26
159	Phenotyping sensory nerve endings in vitro in the mouse. Nature Protocols, 2009, 4, 174-196.	5.5	152
160	Morphological characterization of rat Mas-related G-protein-coupled receptor C and functional analysis of agonists. Neuroscience, 2008, 151, 242-254.	1.1	27